The effect of vitamin D supplementation on the progression of benign prostatic hyperplasia: A randomized controlled trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc in the context of hyperparathyroidism, published as a randomized controlled trial.

Inflammation and proliferation are the cause of benign prostatic hyperplasia (BPH) and are the key components of its mechanism of action.

In this study the researchers sought to determine the role of 25-hydroxyvitamin D in BPH, because of its anti-inflammatory activities, and its effect on prostate volume and BPH symptoms.

Repeated measure analysis was used to evaluate the effect of vitamin D intervention on the changes in the IPSS score.

Who Took Part

The study group was 108 participants.

PubMed indexes the participants as middle-aged adults and older adults, men only.

This randomized clinical trial (RCT) was conducted on 108 participants >50 years of age who had either asymptomatic or mild BPH symptoms according to the International Prostate Symptom Score (IPSS) questionnaire.

Patients were randomly divided into two groups, intervention and control.

How the Study Was Run

The design is described as randomized and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

Prostate ultrasound, routine clinical examinations, toucher rectal (TR), and laboratory tests were performed for all patients.

Results of the evaluations before and after the intervention were compared between the groups using the chi-square, t-test, and logistic regression analysis.

What Was Measured

PubMed files the paper under topics including Anti-Inflammatory Agents, Dietary Supplements, Disease Progression, Iran, Prostate, Prostate-Specific Antigen and Prostatic Hyperplasia.

Author keywords: Benign prostate hypertrophy, Inflammation, Proliferation and Vitamin D.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 108 participants in people with hyperparathyroidism.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2021 (Clinical nutrition (Edinburgh, Scotland)), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Hyperparathyroidism research.